An article from
Dive Brief
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment Sanofi once hailed as a future blockbuster.
Published July 24, 2026
Courtesy of Sanofi
Sanofi halts development of troubled immune drug in eczema
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
476 words~2 min read
